{"product_id":"amicusrx-business-model-canvas","title":"Amicus Therapeutics Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmicus Therapeutics BMC: Rare-Disease Strategy, Partnerships \u0026amp; Revenue Insights — Download\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic core of Amicus Therapeutics with our concise Business Model Canvas—highlighting its value propositions, specialized partnerships, and revenue levers that drive rare-disease growth; download the full Word\/Excel canvas to access section-by-section analysis, financial implications, and ready-to-use slides for investors, advisors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eContract manufacturing organizations supply the specialized biologics capacity Amicus needs to produce Pombiliti and Opfolda, letting Amicus scale to meet demand without the $200–400M cost of new plants; in 2024 Amicus reported supply-chain agreements covering capacity for ~50k annual treatment courses. This outsourcing keeps global supply steady and compliant with FDA\/EMA GMP standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Patient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrategic alliances with global patient advocacy groups for Fabry and Pompe diseases inform patient needs and sped up enrollment—Amicus reported partnership-led recruitment cut trial timelines by ~20% in 2024 and cited 30% higher retention in patient-engaged cohorts; these groups shape patient-centric protocols, drive awareness campaigns reaching \u0026gt;200,000 stakeholders in 2024, and help align Amicus’s pipeline with real-world patient experience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with universities and genetic centers supply Amicus Therapeutics with early-stage leads and platform tech, contributing to 28% of its R\u0026amp;D pipeline discoveries in 2024 and lowering preclinical costs by an estimated $12–18M per program.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Systems and Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmicus Therapeutics negotiates value-based agreements and reimbursements with national health services and private insurers to broaden access to high-cost orphan drugs like Galafold, which generated $367 million in 2024 global net product revenue.\u003c\/p\u003e\n\u003cp\u003eOngoing payer dialogue supports real-world evidence collection to prove long-term clinical and economic value, aiding adoption across Europe, the US, and Japan where rare-disease budgets and HTA scrutiny are rising.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGalafold 2024 revenue: $367M\u003c\/li\u003e\n\u003cli\u003eValue-based contracts: used in EU\/US markets\u003c\/li\u003e\n\u003cli\u003eFocus: real-world evidence, HTA alignment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Logistics and Distribution Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with cold-chain logistics firms (e.g., Marken, UPS Healthcare) secure temperature-controlled delivery of Amicus Therapeutics’ enzyme replacement therapies, reducing spoilage risk—cold-chain failure rates average \u0026lt;1.5% in pharma supply chains (2024 McKinsey).\u003c\/p\u003e\n\u003cp\u003eThese partners handle international customs, GDP compliance, and insulated transport across 40+ markets where Amicus operates, keeping products within required 2–8°C windows from plant to specialty pharmacies and hospitals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain failure ≤1.5% (2024)\u003c\/li\u003e\n\u003cli\u003eCompliance: GDP, temp logs, chain-of-custody\u003c\/li\u003e\n\u003cli\u003eCoverage: 40+ international markets\u003c\/li\u003e\n\u003cli\u003eTarget temp: 2–8°C for ERTs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGalafold: $367M 2024, 50k courses, 40+ markets; advocacy cuts trials 20%, saves $12–18M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCMOs supply capacity for Pombiliti\/Opfolda avoiding $200–400M plant costs; 2024 supply agreements cover ~50k annual courses. Patient-advocacy alliances cut trial timelines ~20% and raised retention 30% in 2024. University collaborations drove 28% of 2024 R\u0026amp;D leads, saving ~$12–18M per program. Galafold revenue $367M (2024); cold-chain failure ≤1.5%; coverage 40+ markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGalafold revenue\u003c\/td\u003e\n\u003ctd\u003e$367M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual treatment capacity (supply deals)\u003c\/td\u003e\n\u003ctd\u003e~50,000 courses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial timeline reduction (advocacy)\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention uplift (advocacy)\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D leads from academia\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical cost savings\/program\u003c\/td\u003e\n\u003ctd\u003e$12–18M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain failure rate\u003c\/td\u003e\n\u003ctd\u003e≤1.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket coverage\u003c\/td\u003e\n\u003ctd\u003e40+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Amicus Therapeutics mapping nine blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—aligned to its rare-disease gene therapy and enzyme replacement strategy, with competitive advantages, SWOT-linked insights, and polished narrative for presentations and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Amicus Therapeutics’ business model with editable cells, designed to quickly identify core therapeutic, R\u0026amp;D, partnership, and commercialization components to relieve strategic planning pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics invests heavily in discovery and clinical development for lysosomal storage and rare diseases, spending $225.6M on R\u0026amp;D in 2024 to run complex trials and expand indications; it combines proprietary pharmacological chaperone technology to improve protein stability with enzyme enhancement and vector platforms. Continuous R\u0026amp;D supports next‑gen gene therapies and label expansion for Galafold (migalastat) and pipeline assets, aiming to reduce time‑to‑approval and increase peak sales potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Commercial Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal Commercial Operations drives the phased launch and market expansion of Pombiliti and Opfolda, targeting 20+ priority markets with a mix of specialty sales teams and digital outreach; Amicus allocated an estimated $220M commercial budget in 2024 for launch readiness. It builds tailored marketing for rare-disease centers, navigates local reimbursement and regulatory pathways, and leverages HCP networks to hit annual patient-access targets (e.g., 2025 goal: 3,500 treated patients).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics must clear FDA, EMA and other regulators—where clinical and CMC reviews average 10–18 months—to commercialize therapies; in 2024 Amicus reported $287m R\u0026amp;D spend, much tied to regulatory submissions. Ongoing tasks cover post‑marketing surveillance, pharmacovigilance and GMP compliance amid evolving ICH and EU pharma rules, since sustaining licenses is required for legal sale and global distribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Support and Access Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmicus Assist runs patient support and access programs that guide patients through insurance, provide copay\/financial aid, and deliver adherence coaching so families start and stay on therapies; in 2024 Amicus reported support to over 7,400 patients and helped secure coverage for therapies in 85% of initiated cases.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFinancial aid: copay assistance, grants\u003c\/li\u003e\n\u003cli\u003eCoverage success: ~85% approval rate (2024)\u003c\/li\u003e\n\u003cli\u003ePatients supported: \u0026gt;7,400 (2024)\u003c\/li\u003e\n\u003cli\u003eServices: education, case management, adherence coaching\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Biomanufacturing Oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmicus enforces strict product purity and potency standards—critical for safety and efficacy—through active oversight of CDMOs and its own facilities; in 2024 the company reported zero lot rejections for its commercial migalastat batches and maintained \u0026gt;99.5% potency in released lots.\u003c\/p\u003e\n\u003cp\u003eThis oversight reduces supply risk and preserves clinician trust, supporting revenue continuity (Q4 2024 product net sales grew 18% year-over-year to $76.2M) and lowering recall-related costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eZero lot rejections reported in 2024\u003c\/li\u003e\n\u003cli\u003e99.5% average potency on released lots\u003c\/li\u003e\n\u003cli\u003eQ4 2024 product net sales $76.2M (+18% YoY)\u003c\/li\u003e\n\u003cli\u003eActive audits of CDMOs and internal sites quarterly\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmicus scales rare disease R\u0026amp;D, launches Pombiliti\/Opfolda, $76.2M Q4 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmicus focuses R\u0026amp;D and clinical ops on lysosomal and rare diseases (R\u0026amp;D $225.6M–$287M in 2024), commercial launch\/market access for Pombiliti\/Opfolda (~$220M commercial spend 2024) and patient support (\u0026gt;7,400 patients, 85% coverage success), plus GMP oversight (zero lot rejections, \u0026gt;99.5% potency) to sustain sales ($76.2M Q4 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2024 key metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$225.6M–$287M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial budget\u003c\/td\u003e\n\u003ctd\u003e$220M (est)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients supported\u003c\/td\u003e\n\u003ctd\u003e7,400+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoverage success\u003c\/td\u003e\n\u003ctd\u003e85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 product sales\u003c\/td\u003e\n\u003ctd\u003e$76.2M (+18% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLot rejections\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotency released lots\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Amicus Therapeutics Business Model Canvas—not a mockup—and it’s the same document you’ll receive after purchase, complete and ready to use.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll download this exact file with all content intact, fully editable for presentations, analysis, or planning—no surprises or filler pages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749619478905,"sku":"amicusrx-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/amicusrx-business-model-canvas.png?v=1772215997","url":"https:\/\/matrixbcg.com\/products\/amicusrx-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}